RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for
patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company. The company trades on NASDAQ exchange. The company headquarter is located in South San Francisco, CA. The company was established in the 2015.
| Ticker | RAPT |
| Long Name | Rapt Therapeutics, Inc. |
| Short Name | Rapt Therapeutics |